COVAX "Contract for 350 Million Doses of Novavax Vaccine Candidate"

[Image source=Yonhap News]

[Asia Economy Reporter Buaeri] The Global Alliance for Vaccines and Immunization (Gavi) announced on the 6th (local time) that it has signed a pre-purchase agreement for 350 million doses of the vaccine candidate from the U.S. pharmaceutical company Novavax on behalf of COVAX.

COVAX is an international project for the joint purchase and distribution of COVID-19 vaccines.

Gavi expects Novavax to be able to supply the vaccine from the third quarter of this year through next year once it receives the relevant regulatory approvals.

Distribution through COVAX requires emergency use authorization from the World Health Organization (WHO).

So far, WHO has approved the emergency use of COVID-19 vaccines developed by Pfizer, AstraZeneca, Janssen, and Moderna.

The development of Novavax's vaccine candidate was invested in by CEPI (Coalition for Epidemic Preparedness Innovations), an international private organization leading COVAX along with Gavi and WHO.

Seth Berkley, CEO of Gavi, said, "The agreement with Novavax is a significant step toward our goal of delivering 2 billion safe and effective vaccine doses in 2021."

This content was produced with the assistance of AI translation services.